Relative Risks of Relapse, Treatment Failure or Death after ABMT for AML in CR1
| . | Poor Prognostic Factor . | RR (95% CI) . | P . |
|---|---|---|---|
| Relapse | Poor cytogenetics | 2.19 (1.89-2.51) | .003 |
| Not FAB M3 | 1.91 (1.78-2.07) | .04 | |
| Treatment failure | Poor cytogenetics | 1.83 (1.60-2.09) | .01 |
| Not FAB M3 | 2.35 (2.17-2.51) | .006 | |
| Death | Not FAB M3 | 2.82 (2.57-3.05) | .004 |
| Short int CR-BMT | 2.73 (1.95-3.77) | .01 |
| . | Poor Prognostic Factor . | RR (95% CI) . | P . |
|---|---|---|---|
| Relapse | Poor cytogenetics | 2.19 (1.89-2.51) | .003 |
| Not FAB M3 | 1.91 (1.78-2.07) | .04 | |
| Treatment failure | Poor cytogenetics | 1.83 (1.60-2.09) | .01 |
| Not FAB M3 | 2.35 (2.17-2.51) | .006 | |
| Death | Not FAB M3 | 2.82 (2.57-3.05) | .004 |
| Short int CR-BMT | 2.73 (1.95-3.77) | .01 |
Adjustment was made for WBC at diagnosis, bone marrow purging, and year of ABMT.
Abbreviations: ABMT, autologous bone marrow transplantation; AML, acute myeloblastic leukemia; CR1, first complete remission; RR, relative risk; CI, confidence interval; FAB, French-American-British classification; int CR-BMT, time interval from complete remission to bone marrow transplantation.